Get started
Work

Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer

Year: 2018
Type: article
Abstract: Background: Tumor cells harboring select genetic abnormalities (eg, BRD3/4-NUT) have shown sensitivity to BET inhibition. BMS-986158, a potent, selective and orally bioavailable BET inhibitor (BETi) was active in several established and pt-derived tumor xenograft models (Gavai AV, et al. AACR 2018; Wee S, et al. AACR 2018). Here we present initial data for BMS-986158 monotherapy from a phase 1/2a trial in previously treated pts with advanced cancer (NCT02419417).
DOI: 10.1093/annonc/mdy279.399
Authors: J. Hilton, M.C. Cristea, M. Voskoboynik, S. Postel-Vinay, W. Edenfield, A. Gavai, S. Wee, N. Srivastava, A. Klippel, D. Jackson, A. Apfel, S.D. Chasalow, D. Williams, M. Donovan, B. Fischer, S. Khaldoyanidi, J.R. Diamond
Institutions: Ottawa Hospital, City Of Hope National Medical Center, Monash University, Institut Gustave Roussy, Prisma Health, Bristol-Myers Squibb (United States), University of Colorado Anschutz
Language: English
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2895961390
FWCI: 0.859
Cites:
Cited by: 23
Related to: 10